Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

NCT03955783 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma

Interventions

DRUG: Venetoclax
DRUG: Selinexor

Sponsor

Sanjay Mohan

Collaborators

[object Object]
[object Object]